10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
13.35
+0.03 (0.23%)
Nov 21, 2024, 12:39 PM EST - Market open
10x Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 629.74 | 618.73 | 516.41 | 490.49 | 298.85 | 245.89 | Upgrade
|
| Revenue Growth (YoY) | 6.56% | 19.81% | 5.28% | 64.13% | 21.53% | 68.06% | Upgrade
|
| Cost of Revenue | 210.13 | 209.41 | 120.09 | 74.09 | 58.47 | 61.03 | Upgrade
|
| Gross Profit | 419.61 | 409.31 | 396.32 | 416.4 | 240.38 | 184.86 | Upgrade
|
| Selling, General & Admin | 331.03 | 336.03 | 295.8 | 257.56 | 202.33 | 130.83 | Upgrade
|
| Research & Development | 260.2 | 268.23 | 264.27 | 211.75 | 123.38 | 83.1 | Upgrade
|
| Operating Expenses | 591.22 | 604.26 | 560.07 | 469.31 | 325.7 | 213.93 | Upgrade
|
| Operating Income | -171.62 | -194.95 | -163.74 | -52.91 | -85.32 | -29.07 | Upgrade
|
| Interest Expense | -0.01 | -0.03 | -0.48 | -0.87 | -1.68 | -3.08 | Upgrade
|
| Interest & Investment Income | 19.06 | 16.91 | 6.65 | 0.21 | 1.53 | 2.81 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.2 | 1.2 | 0.2 | -0.9 | 1.3 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.75 | 0.21 | -0.4 | 0.1 | 0.04 | -0.29 | Upgrade
|
| EBT Excluding Unusual Items | -147.62 | -176.67 | -157.77 | -54.38 | -84.14 | -29.53 | Upgrade
|
| Merger & Restructuring Charges | -4.5 | -4.5 | -4.2 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | -1.72 | - | - | - | - | Upgrade
|
| Asset Writedown | -4.22 | -4.9 | - | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | 0.66 | -1.27 | -1.5 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.52 | - | Upgrade
|
| Pretax Income | -175.92 | -248.76 | -161.97 | -53.72 | -534.48 | -31.03 | Upgrade
|
| Income Tax Expense | 6.63 | 6.34 | 4.03 | 4.51 | 8.26 | 0.22 | Upgrade
|
| Net Income | -182.55 | -255.1 | -166 | -58.22 | -542.73 | -31.25 | Upgrade
|
| Net Income to Common | -182.55 | -255.1 | -166 | -58.22 | -542.73 | -31.25 | Upgrade
|
| Shares Outstanding (Basic) | 120 | 117 | 114 | 110 | 101 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 117 | 114 | 110 | 101 | 39 | Upgrade
|
| Shares Change (YoY) | 3.00% | 2.90% | 3.18% | 9.09% | 158.76% | 191.89% | Upgrade
|
| EPS (Basic) | -1.53 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | Upgrade
|
| EPS (Diluted) | -1.53 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | Upgrade
|
| Free Cash Flow | 26.04 | -63.8 | -165.27 | -122.65 | -254.56 | -8.12 | Upgrade
|
| Free Cash Flow Per Share | 0.22 | -0.54 | -1.45 | -1.11 | -2.52 | -0.21 | Upgrade
|
| Gross Margin | 66.63% | 66.15% | 76.75% | 84.89% | 80.44% | 75.18% | Upgrade
|
| Operating Margin | -27.25% | -31.51% | -31.71% | -10.79% | -28.55% | -11.82% | Upgrade
|
| Profit Margin | -28.99% | -41.23% | -32.15% | -11.87% | -181.61% | -12.71% | Upgrade
|
| Free Cash Flow Margin | 4.14% | -10.31% | -32.00% | -25.01% | -85.18% | -3.30% | Upgrade
|
| EBITDA | -134.77 | -159.44 | -138.38 | -31.8 | -71.31 | -22.01 | Upgrade
|
| EBITDA Margin | -21.40% | -25.77% | -26.80% | -6.48% | -23.86% | -8.95% | Upgrade
|
| D&A For EBITDA | 36.85 | 35.51 | 25.37 | 21.12 | 14.01 | 7.07 | Upgrade
|
| EBIT | -171.62 | -194.95 | -163.74 | -52.91 | -85.32 | -29.07 | Upgrade
|
| EBIT Margin | -27.25% | -31.51% | -31.71% | -10.79% | -28.55% | -11.82% | Upgrade
|
| Advertising Expenses | - | 3.3 | 3.7 | 4.7 | 1.9 | 1.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.